Go Ad-Free
    My Alerts
    Moneycontrol
    Moneycontrol PRO
    Loans
    Loans
    HomeNewsHalol facility

    Halol Facility

    Jump to

    • Centre incentivizing R&D a positive step to encourage investment in innovation, says C.S. Muralidharan of Sun Pharma

      Sun Pharma says it has a very clear strategic intent to invest in its specialty business in core therapeutic areas. 

    • Adulteration concerns: US FDA warning letter to Sun Pharma questions manufacturing practices at Halol facility  

      Violations include not cleaning equipment used to manufacture drugs and failing to prevent contamination, leading to adulteration, the FDA said. The US regulator has asked the firm to immediately assess global manufacturing operations to ensure its products conform to standards.

    • Planning 10 percent expansion of field force in FY23: C.S. Muralidharan, Sun Pharma

      Buoyed by the success of it's field force expansion two years ago, Sun Pharma is planning another round of expansion in the current fiscal to enhance brand focus.

    • FDA made 9 observations post Halol unit inspection: Sun Pharma

      The United States Food and Drug Administration (USFDA) inspected the Halol facility from November 17, 2016 through December 1, 2016, Sun Pharma said in a BSE filing.

    • Integration costs to continue into FY16: Sun Pharma

      Sun Pharma CFO Uday Baldota said given the complexity of the merger, it is difficult to give guidance for FY16, adding that the company is undertaking remediation plans for all Ranbaxy facilities.

    • Peugeot-GM tie-up may use Gujarat facility for car making

      It is becoming increasingly clear that India is going to play a very key role in the global alliance between General Motors and Peugeot Citroen. Sources say that the two companies are currently discussing the viability of Peugeot Citroen using General Motor India’s Halol facility in Gujarat, reports Ronojoy Banerjee of CNBC-TV18.

    Advisory Alert: It has come to our attention that certain individuals are representing themselves as affiliates of Moneycontrol and soliciting funds on the false promise of assured returns on their investments. We wish to reiterate that Moneycontrol does not solicit funds from investors and neither does it promise any assured returns. In case you are approached by anyone making such claims, please write to us at grievanceofficer@nw18.com or call on 02268882347